These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 8709214)

  • 1. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
    Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
    J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
    de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
    Lacey SF; Larder BA
    J Virol; 1994 May; 68(5):3421-4. PubMed ID: 7512165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP.
    Pokholok DK; Gudima SO; Yesipov DS; Dobrynin VN; Rechinsky VO; Kochetkov SN
    FEBS Lett; 1993 Jul; 325(3):237-41. PubMed ID: 7686510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
    Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT
    J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP; Moonis M; Chou TC; Hirsch MS
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.